Market Overview
Global Drugs for Infectious Diseases Caused by Neisseria Gonorrhoeae market was valued at USD 1.21 billion in 2024. The market is projected to grow from USD 1.28 billion in 2025 to USD 1.81 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period.
Drugs for infectious diseases caused by Neisseria gonorrhoeae represent a critical class of antimicrobial agents targeting gonorrhea and related infections. These include third-generation cephalosporins (such as ceftriaxone), tetracyclines (like doxycycline), macrolides (including azithromycin), and aminoglycosides (e.g., gentamicin). Due to the bacterium's notorious antibiotic resistance patterns, treatment protocols require strict adherence to evolving clinical guidelines and regional susceptibility profiles.
USD 1.21 billion in 2024
2032 USD 1.81 billion by 2032
of 5.8%
Ceftriaxone Dominates the Market Due to its Efficacy Against Resistant Strains
The market is segmented based on type into:
Ceftriaxone
Subtypes: Injectable formulations, combination therapies
Doxycycline
Azithromycin
Gentamicin
Others
By Application
Hospital Segment Leads Due to Requirement for Supervised Treatment
Protocols
The market is segmented based on application into: Hospital
Our Key Players
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (UK)
Merck & Co., Inc. (U.S.)
Roche Holding AG (Switzerland)
Astellas Pharma Inc. (Japan)
Sanofi (France)
Bayer AG (Germany)
https://www.24lifesciences.com/dow
https://www.24lifesciences.com
